Product Data Sheet

MLS1547

 Cat. No.:
 HY-128121

 CAS No.:
 315698-36-3

 Molecular Formula:
 C₁₉H₁₉ClN₄O

 Molecular Weight:
 354.83

Target: Dopamine Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 33.33 mg/mL (93.93 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8183 mL	14.0913 mL	28.1825 mL
	5 mM	0.5637 mL	2.8183 mL	5.6365 mL
	10 mM	0.2818 mL	1.4091 mL	2.8183 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (3.52 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 1.25 mg/mL (3.52 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (3.52 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (K_i =1.2 μ M). MLS1547 stimulates D2R G protein-mediated signaling (EC₅₀=0.37 μ M in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β -arrestin recruitment to the D2R (IC₅₀=9.9 μ M)[1][2].

In Vitro

MLS1547 fully antagonizes dopamine-mediated β -arrestin recruitment to the D2R in the DiscoveRx assay, with an IC $_{50}$ of 9.9 μ M. Similar results were obtained when MLS1547 was examined for antagonist activity in the D2R β -arrestin BRET assay, demonstrating an IC $_{50}$ of 3.8 μ M. MLS1547 is found to completely displace [3 H]methylspiperone binding to the D2R, with a

calculated K_i of 1.2 $\mu M^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Free RB, et al. Discovery and characterization of a G protein-biased agonist that inhibits β -arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 2014;86(1):96-105.

[2]. Chun LS, et al. Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Front Synaptic Neurosci. 2018;10:2. Published 2018 Feb 21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com